• Jiri Bartek, Kristin Sjåvik, Samuel Schaible, Sasha Gulati, Ole Solheim, Petter Förander, and Asgeir Store Jakola.
• Department of Clinical Neuroscience and Department of Medicine, Karolinska Institutet, Stockholm, Sweden and Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark. Electronic address: jiri.bartek@karolinska.se.
• World Neurosurg. 2018 May 1; 113: e555-e560.

ObjectiveTo investigate the role of angiotensin converting enzyme (ACE) inhibitors in the recurrence of chronic subdural hematoma (cSDH) after burr hole surgery.MethodsA retrospective review was conducted of a Scandinavian multicenter, population-based cohort of 1252 adults with cSDH who underwent with burr hole surgery between January 1, 2005, and December 31, 2010. The risk of cSDH recurrence was assessed in users of ACE inhibitors, users of angiotensin II receptor blockers (ARBs), and those without ACE inhibitor treatment (no ACE inhibitor group) using univariable and multivariable regression analyses.ResultsThe cohort included 98 (7.8%) ACE inhibitor users and 63 (5%) ARB-only users. The recurrence rate was 16.3% (n = 16) in the ACE inhibitor group, compared with 13.3% (n = 153) in the no ACE inhibitor group (P = 0.39) and 14.3% (n = 9) in the ARB group (P = 0.73). When comparing groups, age (P = 0.01), Charlson Comorbidity Index (P = 0.01), use of platelet inhibitors (P = 0.001) and use of anticoagulants (P = 0.01) differed between the ACE inhibitor and no ACE inhibitor groups. Only age differed significantly between the ACE inhibitor and ARB groups (P = 0.03). In the analyses adjusted for differences in baseline characteristics, ACE inhibitor treatment did not influence the risk of recurrence (odds ratio, 1.2; 95% confidence interval, 0.7-2.2; P = 0.46).ConclusionIn this population-based study, the use of ACE inhibitors was not associated with the risk of recurrence following burr hole surgery for cSDH.Copyright © 2018 Elsevier Inc. All rights reserved.

22 keywords...

hide…